Vanda (VNDA) director donates 25,836 shares of common stock
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray reported a charitable gift of 25,836 shares of common stock, valued at $0.00 per share, using transaction code "G" for a bona fide gift. This donation was made to a charitable organization, and Ray now directly holds 71,246 shares of VNDA common stock. The transaction is a non-market event and does not represent open-market buying or selling activity.
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest
Vanda Pharmaceuticals (VNDA) shares experienced a significant drop following a regulatory setback announcement and are now seeing increased short interest. The article explores the company's business model, its reliance on a concentrated portfolio of drugs for revenue, and the impact of the regulatory decision on its stock performance and investor sentiment. It highlights the inherent volatility for mid-cap biotechs like Vanda due to regulatory and pipeline risks.
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops
Vanda Pharmaceuticals reported a challenging Q1 2026, missing EPS and revenue forecasts, which led to a 13.53% drop in its stock price during after-hours trading. The company's EPS loss was $0.82 against an expected $0.69 loss, and revenue reached $51.7 million, below the $55.04 million forecast. Despite strong year-over-year growth for Fanapt, HETLIOZ sales were impacted by generic competition, and the company projects continued challenges with conservative revenue forecasts for upcoming quarters while anticipating positive contributions from new product launches like NEREUS.
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G
State Street Corporation has reported a beneficial ownership of 3,015,562 shares, representing a 5.1% stake in Vanda Pharmaceuticals (VNDA), as detailed in a Schedule 13G filing on March 31, 2026. This filing indicates a passive investment, with shared voting power of 2,935,448 shares and shared dispositive power of 3,015,562 shares, held across multiple State Street advisory entities.
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops
Vanda Pharmaceuticals reported a challenging Q1 2026, missing EPS and revenue forecasts, which caused a 13.53% stock drop in after-hours trading. Despite a strong annual growth in Fanapt sales, HETLIOZ faced pressure from generic competition. The company is strategically focused on new product launches like NEREUS and BYSANTI to drive future growth.
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs
H.C. Wainwright lowered its price target for Vanda Pharmaceuticals (NASDAQ:VNDA) from $24 to $21, while maintaining a Buy rating, due to anticipated higher operating expenses. This adjustment followed the company's Q1 2026 results, where net product sales of $51.7 million missed H.C. Wainwright's forecast, despite a 94% gross profit margin. The analyst report also noted that Vanda Pharmaceuticals had an EPS of -$0.82, missing the -$0.69 forecast, and revenue of $51.7 million, below the anticipated $55.04 million, yet the stock rose in aftermarket trading.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. announced its participation in three investor conferences in May 2026: the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be livestreamed on Vanda's corporate website. The company is focused on developing and commercializing innovative therapies.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals announced its participation in May 2026 investor conferences. This press release was distributed via Quantisnow, a market data and news platform, which also alerted its Plus members about the announcement. Investors can track Vanda Pharmaceuticals and receive real-time alerts on various market events through Quantisnow.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. announced its participation in three investor conferences in May 2026: the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be broadcast live on Vanda's corporate website. The company is focused on developing and commercializing innovative therapies for unmet medical needs.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation in three investor conferences in May 2026. These include the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be broadcast live on Vanda's corporate website.
Vanda Pharmaceuticals 1Q Loss/Shr 82c >VNDA
Vanda Pharmaceuticals reported a first-quarter loss per share of 82 cents. This financial figure indicates the company's performance for the quarter, reflecting a net loss incurred during that period.
Vanda maps out 3 May investor events, including a live webcast
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in three investor conferences in May 2026: Bank of America Global Health Care (May 12), HCW BioConnect at Nasdaq (May 19), and B. Riley (May 20). A fireside chat will be held on May 19 at the HCW BioConnect event and will be live-streamed and archived on Vanda's investor website. The announcement emphasizes providing additional visibility for investors following recent milestones like the NEREUS™ launch and pivotal imsidolimab data.
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
Vanda Pharmaceuticals (VNDA) is scheduled to participate in three investor conferences in May 2026, including the Bank of America Securities Global Health Care Conference and the HCW 4th Annual BioConnect Investor Conference, where it will hold a fireside chat. The company aims to highlight its advancements in biopharmaceuticals, discuss strategic direction, and enhance investor confidence, reinforcing its commitment to transparency and growth in developing therapies for unmet medical needs.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. announced its Q1 2026 financial results, reporting total net product sales of $51.7 million, a 3% increase year-over-year, but missing earnings expectations with an EPS of $-0.82. The company highlighted strong Fanapt sales growth and the launch of Nirius, along with the FDA approval of Dysanti. Vanda revised its full-year 2026 revenue guidance upwards to $240 million to $290 million, incorporating the potential contribution from Nirius, and discussed progress on its late-stage pipeline including Dysanti, Nirius, and VQW-765.
[10-Q] Vanda Pharmaceuticals Inc. Quarterly Earnings Report
Vanda Pharmaceuticals Inc. reported a Q1 2026 revenue of $51.7 million, a slight increase from the previous year, primarily driven by stronger sales of Fanapt and PONVORY. Despite the revenue growth, the company's net loss widened to $48.6 million due to increased selling, general, and administrative expenses and high research and development costs. Vanda Pharmaceuticals remains focused on its commercial products and pipeline development, with significant regulatory milestones achieved, including FDA approval for BYSANTI and NEREUS, and BLA acceptance for imsidolimab.
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises
Vanda Pharmaceuticals reported a mixed Q1 2026, missing EPS and revenue forecasts but seeing its stock rise due to investor optimism about future product launches like NEREUS and BYSANTI. The company faced increased operating expenses and a significant decrease in cash reserves, yet raised its full-year 2026 revenue guidance. Vanda is focusing on expanding its commercial infrastructure and product pipeline, with several late-stage clinical studies nearing completion.
[EFFECT] Vanda Pharmaceuticals Inc. SEC Filing
This SEC filing for Vanda Pharmaceuticals Inc. (VNDA) is a Notice of Effectiveness for an S-3 form, with an effectiveness date of May 5, 2026, at 9:00 A.M. The filing indicates a "Neutral" impact and sentiment. The article also provides recent news and SEC filings related to Vanda Pharmaceuticals, along with key stock data.
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals has announced the U.S. commercial availability of NEREUS™ (tradipitant), a new prescription medication for the prevention of motion-induced vomiting in adults. This marks the first new pharmacologic treatment for motion sickness in over 40 years, offering a targeted approach by blocking NK-1 receptors in the brain. NEREUS™ is available through traditional pharmacies and a direct-to-consumer platform at nereus.us, where it can be purchased at a discounted cash-pay price.
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades
Vanda Pharmaceuticals has successfully launched Nereus, the first new prescription medication for motion sickness in over four decades. This milestone comes after the D.C.-based company faced several challenges in bringing the drug to market. The drug launch represents a significant achievement for Vanda Pharmaceuticals and its co-founder and CEO, Dr. Mihael Polymeropoulos.
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Relief
Vanda Pharmaceuticals (VNDA) has launched Nereus, a new prescription medication for motion sickness, marking the first such treatment in over four decades. The drug, approved by the FDA, addresses a common condition affecting millions in the U.S. Despite a strong GF Score of 77 and significant market opportunity, recent insider selling of $2.8 million suggests caution for investors.
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years
Vanda Pharmaceuticals has launched Nereus (tradipitant) in the U.S., marking the first new pharmacologic treatment for motion sickness in over 40 years. The company's commercial portfolio also includes therapies for non-24-hour sleep-wake disorder, bipolar I disorder, and inflammatory/autoimmune disorders. Vanda Pharmaceuticals is actively working on several other drug developments and clinical trials, including studying Nereus for GLP-1 side effects.
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals has launched NEREUS™ (tradipitant) in the U.S., making it the first new prescription treatment for motion sickness in over 40 years. This oral neurokinin-1 (NK-1) receptor antagonist is designed to prevent vomiting induced by motion in adults and is available through a direct-to-consumer platform at nereus.us and retail pharmacies. The FDA approved NEREUS™ on December 30, 2025, following successful Phase 3 clinical trials, offering a targeted solution for the millions of Americans affected by motion sickness.
Vanda Pharmaceuticals: NEREUS Brings First New Motion Sickness Treatment In Over 40 Years
Vanda Pharmaceuticals Inc. has launched NEREUS, a new prescription medication for motion sickness, marking the first new treatment in over 40 years. NEREUS, approved by the FDA on December 30, 2025, is a selective neurokinin-1 (NK-1) receptor antagonist that works by blocking the brain's vomiting pathway. It is now available nationwide, with a discounted cash-pay option for patients.
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug
Vanda Pharmaceuticals Inc. (VNDA) saw its stock jump 4% after hours following the commercial launch of its motion sickness drug, Nereus, in the U.S. The FDA approved Nereus in December, marking the first new pharmacologic treatment for motion sickness in over 40 years. The company is also exploring Nereus for gastroparesis and GLP-1 induced nausea and vomiting.
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals has announced the U.S. commercial availability of NEREUS™ (tradipitant), a new prescription medication for preventing vomiting induced by motion in adults. This marks the first new pharmacologic treatment for motion sickness in over 40 years, targeting an issue affecting millions of Americans. NEREUS™ is available through traditional pharmacies and a direct-to-consumer platform, nereus.us, offering a discounted price for cash-pay patients.
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma
The gastroparesis market, valued at approximately USD 240 million in 2023, is projected for significant growth through 2034. Key drivers include rising disease prevalence, particularly among women and older adults, and the emergence of several late-stage clinical therapies from companies like CinDome Pharma, Vanda Pharmaceuticals, and Dr. Falk Pharma GmbH. The United States currently holds the largest share of diagnosed cases and market value, with new interventions and neuropharmacological research presenting opportunities for future treatments.
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss these results and other corporate activities. Investors can access the webcast on Vanda's website, and a replay will be available until May 13, 2026.
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its First Quarter 2026 financial results on Wednesday, May 6, 2026, after the market closes. The company will also host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the webcast on Vanda's website, and a replay will be available until May 13, 2026.
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the webcast on Vanda's website, and a replay will be available until May 13, 2026.
BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A
BlackRock Portfolio Management LLC has filed an amendment to a Schedule 13G/A, indicating beneficial ownership of 2,508,488 shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), which represents 4.2% of the class. The filing specifies that BlackRock holds sole voting power over 2,206,827 shares and sole dispositive power over 2,508,488 shares. This passive institutional holding is below the 5% threshold typically associated with activist investor signaling.
Vanda sets May 6 earnings release, investor call after market close
Vanda Pharmaceuticals (Nasdaq: VNDA) announced it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the results and corporate activities, with a replay available until May 13, 2026. The company provided key financial figures from 2025 and details regarding previous market reactions to similar announcements.
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. A replay of the call will be available until May 13, 2026.
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. announced it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the market closes. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the webcast on Vanda's website, and a replay will be available until May 13, 2026.
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda Pharmaceuticals announced the publication of their pivotal phase III study, "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis," in NEJM Evidence. Imsidolimab, a fully humanized IgG4 monoclonal antibody, is being developed for GPP, a rare orphan indication, with regulatory and patent exclusivity expected into the late 2030s. The findings from this study are part of the Biologics License Application submitted to the FDA, which has a target action date of December 12, 2026.
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
Vanda Pharmaceuticals has published research findings on imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine and submitted a Biologics License Application (BLA) to the FDA for the drug. The company expects regulatory and patent exclusivity for imsidolimab to extend into the late 2030s, providing a long-term market advantage. Vanda holds an exclusive global license for imsidolimab, which will diversify its product portfolio and support future market expansion.
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda Pharmaceuticals announced the publication of their pivotal phase III study, "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis," in NEJM Evidence. These findings support the Biologics License Application (BLA) for imsidolimab, which is being developed to treat Generalized Pustular Psoriasis (GPP) and has a target FDA action date of December 12, 2026. Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling, with regulatory and patent exclusivity expected until the late 2030s.
Rare skin disease drug study appears in NEJM Evidence before FDA date
Vanda Pharmaceuticals announced the publication of pivotal Phase III study results for its drug imsidolimab in NEJM Evidence. This study evaluated imsidolimab's efficacy and safety for treating Generalized Pustular Psoriasis (GPP). The findings are included in a Biologics License Application (BLA) submitted to the U.S. FDA, with a target action date of December 12, 2026, for regulatory approval.
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin
The article "Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin" likely discusses the significant stock movements of these three pharmaceutical companies on a particular Wednesday. Without the actual content, it is impossible to provide details on the reasons behind their stock performance, such as clinical trial results, regulatory news, or financial reports.
Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs
Vanda Pharmaceuticals granted director Duncan Charles Cliff 57,101 time-based restricted stock units (RSUs) with no cash exercise price. This equity award will vest in four equal annual installments, beginning on April 22, 2027, provided he continues his service to the company. Following this grant, Cliff's direct holdings from this award total 57,101 shares.
Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership
Vanda Pharmaceuticals Inc. director Duncan Charles Cliff filed an initial Statement of Beneficial Ownership on Form 3, disclosing his equity position as a director without reporting any transactions. This filing serves as a baseline for his ownership in the company. The Form 3 is a regulatory requirement for insiders to report their initial holdings, providing transparency for investors.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals Inc. announced the appointment of Dr. Charles Duncan to its Board of Directors, a move that expands the board to seven directors, six of whom are independent. Dr. Duncan brings decades of experience in the life sciences and biotechnology sector, having served as a sell-side biotech equity research analyst and currently as President of Sulci Advisors, LLC. His appointment is expected to bolster Vanda's strategic direction during what the company and Dr. Duncan describe as a "potentially transformational period" with new product approvals and an expanding pipeline.
Executive pay, board votes and pipeline in Vanda (NASDAQ: VNDA) 2026 proxy
Vanda Pharmaceuticals is seeking stockholder approval on several proposals at its upcoming virtual 2026 annual meeting on June 4, 2026. Key agenda items include the election of three Class II directors, ratification of PricewaterhouseCoopers as the auditor, an advisory vote on executive compensation, and an increase in authorized shares under the 2016 Equity Incentive Plan. The company reported 2025 total revenue of $216.1 million and a net loss of $220.5 million, while highlighting progress in its late-stage clinical programs and an FDA approval for tradipitant.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced the appointment of Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. Dr. Duncan brings extensive experience from the life sciences and biotechnology sector, having spent nearly three decades as a sell-side biotechnology equity research analyst and currently serving as President of Sulci Advisors, LLC. His expertise in neurology, psychiatry, and platform-enabled therapeutics is expected to significantly contribute to Vanda's innovative pipeline and strategic growth, especially following recent product approvals and label expansions.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to Board of Directors to Drive Growth and Innovation in CNS Therapies 1
Vanda Pharmaceuticals Inc. has appointed Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. Dr. Duncan brings over 30 years of experience in the life sciences and biotechnology sector, particularly in neurology and psychiatry, and his appointment is expected to bolster Vanda's strategic growth and innovation in CNS therapies. This move, alongside recent product approvals and a robust pipeline, positions Vanda for a new era of growth, although investors are cautioned about inherent risks.
Vanda Pharmaceuticals adds Charles Duncan to board By Investing.com
Vanda Pharmaceuticals has appointed Charles Duncan to its board of directors, effective immediately, increasing the board to seven members, six of whom are independent. Duncan, founder of Sulci Advisors and former biotechnology equity research analyst, brings nearly three decades of experience in the life sciences sector. The appointment comes as Vanda expects profitability in fiscal 2026, with strong financial performance and recent product approvals.
Vanda Pharmaceuticals adds Charles Duncan to board
Vanda Pharmaceuticals has appointed Charles Duncan to its board of directors, bringing the total board members to seven. Duncan, founder of Sulci Advisors and a former biotechnology equity research analyst, is expected to contribute significantly to the company. The appointment comes as Vanda Pharmaceuticals celebrates recent product approvals and anticipates profitability for fiscal 2026, with strong financial indicators like 94% gross profit margins and more cash than debt.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals Inc. announced the appointment of Dr. Charles Duncan to its Board of Directors, increasing the board to seven directors, six of whom are independent. Dr. Duncan, founder of Sulci Advisors, LLC, brings extensive experience from nearly three decades as a sell-side biotechnology equity research analyst. He expressed enthusiasm for joining Vanda during what he believes is a transformational period for the company, citing recent approvals and a growing pipeline.
Charles Duncan joins Vanda Pharmaceuticals (NASDAQ: VNDA) board
Vanda Pharmaceuticals has appointed Charles C. Duncan, Ph.D., to its Board of Directors, expanding the board from six to seven members. Dr. Duncan, a Class II director, will receive an initial restricted stock unit award valued at $390,000 and an annual cash fee of $50,000, along with eligibility for further annual RSU awards. His extensive background as a biotechnology equity research analyst and president of Sulci Advisors, LLC, is expected to enhance Vanda's strategic direction, particularly during what the company anticipates as a period of significant growth and innovation in its pipeline.
Vanda Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Vanda Pharmaceuticals, Inc. for potential securities fraud following a significant 14.05% stock price drop on January 8, 2026. This decline was triggered by the FDA's decision not to approve the supplemental New Drug Application for HETLIOZ® in its current form, citing insufficient evidence of effectiveness for jet lag disorder after finding Vanda's clinical trials failed to simulate actual travel conditions adequately. The firm is encouraging investors to contact them to discuss legal rights and potential class action.
Polymeropoulos Christos Vasilios Mihael Net Worth (2026)
This article provides an overview of Polymeropoulos Christos Vasilios Mihael's net worth and insider trading activities, highlighting his ownership in Vanda Pharmaceuticals Inc (VNDA) where he serves as Senior VP & Medical Director. It details that he has made no insider transactions in VNDA recently, while other insiders have conducted net sales of shares. The article also lists key executives at Vanda Pharmaceuticals Inc and summarizes recent insider trading in the company.
